Kevin Lee Freeman Sells 7,500 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT) insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now owns 255,881 shares in the company, valued at $1,847,460.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Health Catalyst Trading Down 1.2 %

NASDAQ HCAT opened at $7.29 on Friday. Health Catalyst, Inc. has a 12 month low of $5.42 and a 12 month high of $11.98. The stock has a 50-day simple moving average of $6.87 and a 200 day simple moving average of $6.93. The company has a market capitalization of $430.37 million, a PE ratio of -3.94 and a beta of 1.31.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The company had revenue of $75.90 million during the quarter, compared to analysts’ expectations of $74.96 million. During the same period in the prior year, the business posted ($0.21) EPS. Health Catalyst’s revenue was up 3.7% on a year-over-year basis. As a group, sell-side analysts predict that Health Catalyst, Inc. will post -0.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Health Catalyst

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC increased its position in shares of Health Catalyst by 461.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after buying an additional 5,232 shares in the last quarter. Quarry LP increased its holdings in shares of Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after acquiring an additional 2,610 shares in the last quarter. Perfromance Wealth Partners LLC acquired a new stake in shares of Health Catalyst during the second quarter worth about $64,000. Mackenzie Financial Corp bought a new position in shares of Health Catalyst during the 2nd quarter valued at about $70,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Health Catalyst in the 1st quarter valued at approximately $98,000. 85.00% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on HCAT. Stephens reduced their target price on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Thursday, August 8th. JPMorgan Chase & Co. boosted their price objective on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday. Canaccord Genuity Group restated a “buy” rating and set a $11.00 target price on shares of Health Catalyst in a report on Tuesday, May 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a report on Tuesday, August 20th. Finally, Evercore ISI decreased their price objective on shares of Health Catalyst from $9.00 to $8.00 and set an “outperform” rating on the stock in a report on Tuesday, July 9th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.42.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.